Drug development firm Icagen (Nasdaq: ICGN) lost $3.6 million in the first quarter of this year as revenues and expenses remained relatively flat compared to a year earlier.

did cut costs by some $400,000.

The company also provided an update on its drug pipeline development efforts, making what Chief Executive Officer P. Kay Wagoner called “progress on our key clinical programs.”